Drugs / CLR325
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02696967 | May 2016 → Jan 2019 | heart failure | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLR325 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02696967 ↗ |
| Route | Intravenous | “CLR325 intravenous (i.v.) infusion” NCT02696967 ↗ |